By
Drug Target Review2025-12-02T14:30:17
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T13:00:00Z
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2026-07-08T07:58:00
Contributor Dr Nick Lynch, By Dr Raminderpal Singh
2026-10-21T14:02:00
Contributor Jim Corbett, By Drug Target Review
2026-07-01T06:30:00
Sponsored by BPS Bioscience, By Dr Veronique Baron
2026-08-03T06:00:00
Author Dr Xiaoxiao Wang, Yan Zhang and Junli Zhao
2026-08-24T08:43:00
Author Dr Dana Watt
Site powered by Webvision Cloud